EMA accepts Eisai, Biogen’s lecanemab MAA for review to treat AD
The European Medicines Agency (EMA) has accepted for review Eisai and Biogen’s marketing authorization application (MAA) submitted for lecanemab to treat early Alzheimer’s disease (AD).